Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Prospects of Treating Prostate Cancer through Apalutamide: A Mini-Review

Author(s): Ranapartap Singh, Yunes M.M.A. Alsayadi, Vikram Jeet Singh, Pooja A. Chawla* and Ravindra Kumar Rawal

Volume 22, Issue 6, 2022

Published on: 04 January, 2022

Page: [1056 - 1067] Pages: 12

DOI: 10.2174/1871520621666210824113736

Price: $65

Abstract

Background: Prostate cancer is considered the second most diagnosed cancer, and one of the most common causes of death from cancer in men. Apalutamide is an effective, safe, and well-tolerated agent used for the treatment of men with non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) and metastatic Hormone-Naive Prostate Cancer (mHNPC). Androgen receptor signaling is a leading factor that drives these prostate tumors. USFDA has approved apalutamide on 14 February 2018 as an agent that targets androgen receptor signaling through inhibition causing significant improvement in metastasis-free survival in patients with prostate cancer.

Objective: In this review, various aspects related to apalutamide have been summarized which involve the mechanism of action, chemistry, synthesis, pharmacokinetics, pharmacodynamics, adverse reactions, and safety parameters.

Methods: The literature was thoroughly searched in the relevant databases to identify studies published in this field during recent years. Special attention has been given to apalutamide clinical trials phases and its promising future as one of the first-line agents for the treatment of patients with advanced prostate cancer.

Results: Ongoing trials are progressing for apalutamide monotherapy and also for its combinations in other disease settings. The expected results of such trials will shape the future scenario of prostate cancer therapy.

Conclusion: This review article has highlighted different aspects of Apalutamide like its mechanism of action, adverse effects, pharmacokinetics, pharmacodynamics, clinical trials among others. The contents of this article should make an excellent read for prospective researchers in this field.

Keywords: Prostate cancer, nmCRPC, mHNPC, androgen receptor inhibitor, apalutamide, monotherapy.

« Previous Next »
Graphical Abstract

[1]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Boukovala, M.; Spetsieris, N.; Efstathiou, E. An evaluation of apalutamide for the treatment of prostate cancer. Expert Opin. Pharmacother., 2020, 21(13), 1537-1546.
[http://dx.doi.org/10.1080/14656566.2020.1770726] [PMID: 32543237]
[3]
Spratt, D.E.; McHugh, D.J.; Morris, M.J.; Morgans, A.K. Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right Time. Am. Soc. Clin. Oncol. Educ. Book, 2018, 38(38), 355-362.
[http://dx.doi.org/10.1200/EDBK_200319] [PMID: 30231323]
[4]
Grönberg, H.; Damber, L.; Damber, J.E. Familial prostate cancer in Sweden. A nationwide register cohort study. Cancer, 1996, 77(1), 138-143.
[http://dx.doi.org/10.1002/(SICI)1097-0142(19960101)77:1<138:AID-CNCR23>3.0.CO;2-5] [PMID: 8630920]
[5]
Kachur, E. Prostate cancer review. US Pharm., 2018, 43(8), HS-7-HS-12.
[6]
Drugs.com Generic Nilandron Availability. Available at:, https://www.drugs.com/availability/generic-nilandron.html(Accessed June 06, 2021).
[7]
Bashir, M.N. Epidemiology of prostate cancer. Asian Pac. J. Cancer Prev., 2015, 16(13), 5137-5141.
[http://dx.doi.org/10.7314/APJCP.2015.16.13.5137] [PMID: 26225642]
[8]
Parkin, D.M.; Bray, F.I.; Devesa, S.S. Cancer burden in the year 2000. The global picture. Eur. J. Cancer, 2001, 37(Suppl. 8), S4-S66.
[http://dx.doi.org/10.1016/S0959-8049(01)00267-2] [PMID: 11602373]
[9]
Staals, E.L.; Ferrari, S.; Donati, D.M.; Palmerini, E. Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives. Eur. J. Cancer, 2016, 63, 34-40.
[http://dx.doi.org/10.1016/j.ejca.2016.04.022] [PMID: 27267143]
[10]
Giri, K.D. Prostate – Introduction Prostate – Introduction. In: National toxicology program; 1-6.
[11]
Kopper, L.; Tímár, J. Genomics of prostate cancer: is there anything to “translate”? Pathol. Oncol. Res., 2005, 11(4), 197-203.
[http://dx.doi.org/10.1007/BF02893851] [PMID: 16388315]
[12]
de Koning, H.J.; Liem, M.K.; Baan, C.A.; Boer, R.; Schröder, F.H.; Alexander, F.E. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int. J. Cancer, 2002, 98(2), 268-273.
[http://dx.doi.org/10.1002/ijc.10188] [PMID: 11857418]
[13]
Tomlins, S.A.; Rhodes, D.R.; Perner, S.; Dhanasekaran, S.M.; Mehra, R.; Sun, X.W.; Varambally, S.; Cao, X.; Tchinda, J.; Kuefer, R.; Lee, C.; Montie, J.E.; Shah, R.B.; Pienta, K.J.; Rubin, M.A.; Chinnaiyan, A.M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 2005, 310(5748), 644-648.
[http://dx.doi.org/10.1126/science.1117679] [PMID: 16254181]
[14]
Andersson, S.O.; Wolk, A.; Bergström, R.; Adami, H.O.; Engholm, G.; Englund, A.; Nyrén, O. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J. Natl. Cancer Inst., 1997, 89(5), 385-389.
[http://dx.doi.org/10.1093/jnci/89.5.385] [PMID: 9060961]
[15]
Smith, M.R.; Saad, F.; Chowdhury, S.; Oudard, S.; Hadaschik, B.A.; Graff, J.N.; Olmos, D.; Mainwaring, P.N.; Lee, J.Y.; Uemura, H.; Lopez-Gitlitz, A.; Trudel, G.C.; Espina, B.M.; Shu, Y.; Park, Y.C.; Rackoff, W.R.; Yu, M.K.; Small, E.J. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med., 2018, 378(15), 1408-1418.
[http://dx.doi.org/10.1056/NEJMoa1715546] [PMID: 29420164]
[16]
Mustafa, M.; Salih, A.F.; Illzam, E.M.; Sharifa, A.M.; Suleiman, M.; Hussain, S.S. Prostate Cancer : Pathophysiology, Diagnosis, and Prognosis, 2016, 15(6), 4-11.
[17]
Horsley, P.J.; Aherne, N.J.; Edwards, G.V.; Benjamin, L.C.; Wilcox, S.W.; McLachlan, C.S.; Assareh, H.; Welshman, R.; McKay, M.J.; Shakespeare, T.P. Planning magnetic resonance imaging for prostate cancer intensity-modulated radiation therapy: Impact on target volumes, radiotherapy dose and androgen deprivation administration. Asia Pac. J. Clin. Oncol., 2015, 11(1), 15-21.
[http://dx.doi.org/10.1111/ajco.12266] [PMID: 25227727]
[18]
Zhao, K.; Wang, C.; Hu, J.; Yang, X.; Wang, H.; Li, F.; Zhang, X.; Zhang, J.; Wang, X. Prostate cancer identification: quantitative analysis of T2-weighted MR images based on a back propagation artificial neural network model. Sci. China Life Sci., 2015, 58(7), 666-673.
[http://dx.doi.org/10.1007/s11427-015-4876-6] [PMID: 26025283]
[19]
Costello, L.C.; Franklin, R.B. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol. Cancer, 2006, 5, 17.
[http://dx.doi.org/10.1186/1476-4598-5-17] [PMID: 16700911]
[20]
Leav, I.; Plescia, J.; Goel, H.L.; Li, J.; Jiang, Z.; Cohen, R.J.; Languino, L.R.; Altieri, D.C. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am. J. Pathol., 2010, 176(1), 393-401.
[http://dx.doi.org/10.2353/ajpath.2010.090521] [PMID: 19948822]
[21]
Narizhneva, N.V.; Tararova, N.D.; Ryabokon, P.; Shyshynova, I.; Prokvolit, A.; Komarov, P.G.; Purmal, A.A.; Gudkov, A.V.; Gurova, K.V. Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer. Cell Cycle, 2009, 8(24), 4155-4167.
[http://dx.doi.org/10.4161/cc.8.24.10316]
[22]
Yao, V.; Berkman, C.E.; Choi, J.K.; O’Keefe, D.S.; Bacich, D.J. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate, 2010, 70(3), 305-316.
[http://dx.doi.org/10.1002/pros.21065] [PMID: 19830782]
[23]
Cockshott, I.D. Bicalutamide: clinical pharmacokinetics and metabolism. Clin. Pharmacokinet., 2004, 43(13), 855-878.
[http://dx.doi.org/10.2165/00003088-200443130-00003] [PMID: 15509184]
[24]
Bambury, R.M.; Scher, H.I. Enzalutamide: Development from bench to bedside. Urol. Oncol., 2015, 33(6), 280-288.
[http://dx.doi.org/10.1016/j.urolonc.2014.12.017] [PMID: 25797385]
[25]
Goldspiel, B.R.; Kohler, D.R. Flutamide: an antiandrogen for advanced prostate cancer. DICP, 1990, 24(6), 616-623.
[http://dx.doi.org/10.1177/106002809002400612] [PMID: 2193461]
[26]
Harris, M.G.; Coleman, S.G.; Faulds, D.; Chrisp, P. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging, 1993, 3(1), 9-25.
[http://dx.doi.org/10.2165/00002512-199303010-00002] [PMID: 8453188]
[27]
Borst, S.E.; Lowenthal, DT ZG. Androgen Biosynthesis Inhibitors and Androgen Receptor Antagonists. Vol. 1. 2004. 210-213 p. Dk., 2015, 53(9), 1689-99.
[28]
U.S. Food & Drug. Drug Innovation - Novel Drug Approvals for 2018. Available at: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm592464.htm (Accessed June 06, 2021).
[29]
Clegg, N.J.; Wongvipat, J.; Joseph, J.D.; Tran, C.; Ouk, S.; Dilhas, A.; Chen, Y.; Grillot, K.; Bischoff, E.D.; Cai, L.; Aparicio, A.; Dorow, S.; Arora, V.; Shao, G.; Qian, J.; Zhao, H.; Yang, G.; Cao, C.; Sensintaffar, J.; Wasielewska, T.; Herbert, M.R.; Bonnefous, C.; Darimont, B.; Scher, H.I.; Smith-Jones, P.; Klang, M.; Smith, N.D.; De Stanchina, E.; Wu, N.; Ouerfelli, O.; Rix, P.J.; Heyman, R.A.; Jung, M.E.; Sawyers, C.L.; Hager, J.H. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res., 2012, 72(6), 1494-1503.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-3948] [PMID: 22266222]
[30]
Koukourakis, M.I.; Kakouratos, C.; Kalamida, D.; Mitrakas, A.; Pouliliou, S.; Xanthopoulou, E.; Papadopoulou, E.; Fasoulaki, V.; Giatromanolaki, A. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines. Anticancer Drugs, 2018, 29(4), 323-333.
[http://dx.doi.org/10.1097/CAD.0000000000000592] [PMID: 29381490]
[31]
Rathkopf, D.E.; Scher, H.I. Apalutamide for the treatment of prostate cancer. Expert Rev. Anticancer Ther., 2018, 18(9), 823-836.
[http://dx.doi.org/10.1080/14737140.2018.1503954] [PMID: 30101644]
[32]
Schweizer, M.T.; Antonarakis, E.S. Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther. Adv. Urol., 2012, 4(4), 167-178.
[http://dx.doi.org/10.1177/1756287212452196] [PMID: 22852027]
[33]
Rathkopf, D.; Scher, H.I. Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J., 2013, 19(1), 43-49.
[http://dx.doi.org/10.1097/PPO.0b013e318282635a] [PMID: 23337756]
[34]
Rathkopf, D.E.; Morris, M.J.; Fox, J.J.; Danila, D.C.; Slovin, S.F.; Hager, J.H.; Rix, P.J.; Chow Maneval, E.; Chen, I.; Gönen, M.; Fleisher, M.; Larson, S.M.; Sawyers, C.L.; Scher, H.I. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J. Clin. Oncol., 2013, 31(28), 3525-3530.
[http://dx.doi.org/10.1200/JCO.2013.50.1684] [PMID: 24002508]
[35]
Pang, X.; Wang, Y.; Chen, Y. Design, synthesis, and biological evaluation of deuterated apalutamide with improved pharmacokinetic profiles. Bioorg. Med. Chem. Lett., 2017, 27(12), 2803-2806.
[http://dx.doi.org/10.1016/j.bmcl.2017.04.071] [PMID: 28478926]
[36]
May, M.B.; Glode, A.E. Apalutamide: A new agent in the management of prostate cancer. J. Oncol. Pharm. Pract., 2019, 25(8), 1968-78.
[37]
Rathkopf, D.E.; Antonarakis, E.S.; Shore, N.D.; Tutrone, R.F.; Alumkal, J.J.; Ryan, C.J.; Saleh, M.; Hauke, R.J.; Bandekar, R.; Maneval, E.C. De, Boer C.J. Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone. Clin. Cancer Res., 2017, 23(14), 3544-51.
[38]
Coutinho, I.; Day, T.K.; Tilley, W.D.; Selth, L.A. Androgen receptor signaling in castration-resistant prostate cancer: A lesson in persistence. Endocr. Relat. Cancer, 2016, 23(12), T179-T197.
[39]
Geynisman, D.M.; Plimack, E.R.; Zibelman, M. Second-generation androgen receptor–targeted therapies in nonmetastatic castration-resistant prostate cancer: Effective early intervention or intervening too early? Eur. Urol., 2016, 6(70), 971-3.
[40]
Geynisman, D.M.; Plimack, E.R.; Zibelman, M. Second-generation androgen receptor–targeted therapies in nonmetastatic castration-resistant prostate cancer: Effective early intervention or intervening too early? Eur. Urol., 2016, 6(70), 971-3.
[41]
Smith, M.R.; Antonarakis, E.S.; Ryan, C.J.; Berry, W.R.; Shore, N.D.; Liu, G.; Alumkal, J.J.; Higano, C.S.; Maneval, E.C.; Bandekar, R.; de Boer, C.J. Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. Eur. Urol., 2016, 70(6), 963-70.
[42]
Chi, K.N.; Agarwal, N.; Bjartell, A.; Chung, B.H.; Pereira de Santana Gomes, A.J.; Given, R.; Juárez Soto, Á.; Merseburger, A.S.; Özgüroğlu, M.; Uemura, H.; Ye, D. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med., 2019, 381(1), 13-24.
[43]
Saad, F.; Cella, D.; Basch, E.; Hadaschik, B.A.; Mainwaring, P.N.; Oudard, S.; Graff, J.N.; McQuarrie, K.; Li, S.; Hudgens, S.; Lawson, J.; Lopez-Gitlitz, A.; Yu, M.K.; Smith, M.R.; Small, E.J. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol., 2018, 19(10), 1404-1416.
[http://dx.doi.org/10.1016/S1470-2045(18)30456-X] [PMID: 30213449]
[44]
Small, E.J.; Saad, F.; Chowdhury, S.; Oudard, S.; Hadaschik, B.A.; Graff, J.N.; Olmos, D.; Mainwaring, P.N.; Lee, J.Y.; Uemura, H.; De Porre, P.; Smith, A.A.; Zhang, K.; Lopez-Gitlitz, A.; Smith, M.R. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Ann. Oncol., 2019, 30(11), 1813-1820.
[http://dx.doi.org/10.1093/annonc/mdz397] [PMID: 31560066]
[45]
Agarwal, N.; McQuarrie, K.; Bjartell, A.; Chowdhury, S.; Pereira de Santana Gomes, A.J.; Chung, B.H.; Özgüroğlu, M.; Juárez Soto, Á.; Merseburger, A.S.; Uemura, H.; Ye, D.; Given, R.; Cella, D.; Basch, E.; Miladinovic, B.; Dearden, L.; Deprince, K.; Naini, V.; Lopez-Gitlitz, A.; Chi, K.N. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol., 2019, 20(11), 1518-1530.
[http://dx.doi.org/10.1016/S1470-2045(19)30620-5] [PMID: 31578173]
[46]
U.S.National Library of Medicine Available at: https://clinicaltrials.gov/ct2/show/NCT04108208(Accessed Feb 04, 2021).
[47]
U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04601441(Accessed Feb 04, 2021).
[48]
Estados Unidos. FDA/CDER. Erleada (apalutamide): Highlights of Prescribing Information. 2018, 1-17. Available at: www.fda.gov/medwatch
[49]
ERLEADA (apalutamide) tablets, for oral use Initial U.S. Approval – 2018. Highlights of Prescribing Information. , 2018; pp. 1-7.
[50]
Graff, J.N.; Baciarello, G.; Armstrong, A.J.; Higano, C.S.; Iversen, P.; Flaig, T.W.; Forer, D.; Parli, T.; Phung, D.; Tombal, B.; Beer, T.M.; Sternberg, C.N. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann. Oncol., 2016, 27(2), 286-294.
[http://dx.doi.org/10.1093/annonc/mdv542] [PMID: 26578735]
[51]
Belderbos, B.P.S.I.; de Wit, R.; Chien, C.; Mitselos, A.; Hellemans, P.; Jiao, J.; Yu, M.K.; Attard, G.; Bulat, I.; Edenfield, W.J.; Saad, F. An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration- resistant prostate cancer. Cancer Chemother. Pharmacol., 2018, 82(3), 457-468.
[http://dx.doi.org/10.1007/s00280-018-3632-6] [PMID: 29974203]

Rights & Permissions Print Cite
Article Metrics
29
1
© 2024 Bentham Science Publishers | Privacy Policy